09
Mar

After gaining an option on Opexa’s experimental drug for secondary progressive multiple sclerosis for only $5 million, Merck KGaA’s Serono division has come up with an extra $3 million to support the biotech’s ongoing Phase IIb study.

…read more

Source: Merck KGaA pitches in an extra $3M to support Opexa’s PhIIb for MS

    

0 No comments